| Reporting Organization: | WHO - World Health Organization |
|---|---|
| Total Budget ($CAD): | $ 9,000,000 |
| Timeframe: | March 10, 2017 - August 31, 2018 |
| Status: | Completion |
| Contact Information: | Unspecified |
WHO - World Health Organization
Unspecified
| Sub-Saharan Africa - $ 2,637,000.00 (29.30%) | |
|
|
|
| South America - $ 2,088,000.00 (23.20%) | |
|
|
|
| Southeast Asia - $ 999,000.00 (11.10%) | |
|
|
|
| Central America - $ 909,000.00 (10.10%) | |
|
|
|
| South Asia - $ 819,000.00 (9.10%) | |
|
|
|
| East Asia - $ 729,000.00 (8.10%) | |
|
|
|
| Central Asia - $ 459,000.00 (5.10%) | |
|
|
|
| North Africa - $ 360,000.00 (4.00%) | |
|
|
|
| Infectious & Communicable Diseases (50 %) | |
|
|
|
| Law, Governance & Public Policy (50 %) | |
|
|
|
This project aims to decrease the impact of antimicrobial resistance (AMR), particularly in low- and middle-income countries. Interventions take place across the first four objectives of the Global Action Plan on AMR, which focus on increasing awareness of AMR as a public health threat; improving capacity to monitor AMR patterns, consumption and use; strengthening capacity in infection prevention and control; and strengthening systems to optimize use of antibiotics. The project also includes a component that reinforces linkages to combat AMR across the World Health Organization, with Member States and partners. The Public Health Agency of Canada is a technical partner in this project.
| Gender and age: | Unspecified |
|---|---|
| Total Direct Population: | Unspecified |
Unspecified
Return to topThe expected intermediate outcomes of this project include: (1) enhanced coordination and evidence-based policy-making and planning among national and international actors; and (2) enhanced responsible and effective use of antibiotics at hospital and community level in selected low- and middle-income countries.
Results achieved by WHO through the support of the Government of Canada and other international donors in 2017-2018 include: (1) strengthened health systems in low- and middle-income countries through the development of national action plans (NAPs) on antimicrobial resistance (AMR) and improvements in the prevention and treatment of infectious diseases; (2) improved data collection on and knowledge around the use of antimicrobial drugs to inform policy and practice and implement NAPs; and (3) strengthened global AMR surveillance systems to guide appropriate action on the consumption, use, quality and safety of medicines to ensure the ability to treat and prevent infectious diseases.
